Navigation Links
Mass. General Hospital, Iacocca Foundation announce completion of Phase I diabetes trial

Massachusetts General Hospital (MGH) and the Iacocca Foundation announce today the completion of the Phase I BCG clinical trial in type 1 diabetes, as well as the submission of all safety reports to the U.S. Food and Drug Administration (FDA) and the MGH data safety monitoring boards. Plans for the Phase II clinical study, which will continue the investigation of bacillus Calmette-Guerin (BCG) vaccination as a treatment for people with existing type 1 diabetes, are actively underway.

"We are making great progress and are really excited to be able to move this potential treatment to the next stage of clinical testing," says Denise Faustman, MD, PhD, director of the Immunobiology Laboratory at the MGH and an associate professor of Medicine at Harvard Medical School.

The results of the MGH trial showed that low-dose, multi-dosing regimens of BCG vaccination were safe in individuals with type 1 diabetes. There were no severe reactions to the vaccine other than the expected inflammation at the injection sites. BCG is a generic drug that is currently approved in the United States for tuberculosis vaccination and for the treatment of bladder cancer.

"This clinical trial is an important event for both the MGH and the Iacocca Foundation, who have been our partners in this process," says Peter Slavin, MD, president and CEO of Massachusetts General Hospital. "We are putting our energies behind moving the trial into Phase II."

The MGH Immunobiology lab, led by Faustman, will now begin planning for a Phase II clinical trial to continue investigating the safety and efficacy of BCG vaccination as a therapeutic agent for the prevention or reversal of type 1 diabetes. The trial will seek to define the exact dose and timing of administration of BCG vaccination to treat advanced type 1 diabetes. The majority of the funds for Faustman's basic research, on which these human studies are based, have come from the Iacocca Foundation. Additional information about the clinical trials can be found at

"We are very pleased to see this work come as far as it has," says Lee A. Iacocca, chairman of the Iacocca Foundation. "I made a promise to see a cure for type 1 diabetes in my lifetime, and I intend to keep it. The public support of this trial and a trial for people with this disease is my dream."

The MGH clinical trial was a double-blind, placebo-controlled Phase I human clinical trial to evaluate the safety of BCG vaccination in volunteers with type 1 diabetes. The basis of the trial is preclinical work done in the Faustman Immunobiology Laboratory, as well as other laboratories worldwide, showing that temporarily elevating levels of an immune modulator called tumor necrosis factor (TNF) can eliminate the abnormal white blood cells found in mice and humans with type 1 diabetes. Administration of the BCG vaccine is known to raise TNF levels in humans.


Contact: Sue McGreevey
Massachusetts General Hospital

Related medicine news :

1. Mass. Eye and Ear receives NEI grant renewal for growing clinical/scientists
2. Mass. General Hospital to create registry for coronary optical coherence tomography
3. Mass. Eye and Ear Infirmary Cataract Surgery Trainer teaches residents cataract surgery
4. Clear rules facilitate continued Web interaction among general practitioners
5. Survey finds general internists leave practice sooner than subspecialists
6. Miles for Hope’s Moving Towards A Cure(SM) Brain Tumor Walk in Boston Raising Funds for Brain Tumor Vaccine and Massachusetts General Hospital
7. Pennsylvania Attorney General Corbett Will File Lawsuit to Block Health Care Reform Legislation
8. Deep brain stimulation reduces epileptic seizures in patients with refractory partial and secondarily generalized seizures
9. AdvancedMD Appoints William Stone Vice President and General Manager of Billing Services Partner Program
10. Delphi Healthcare Parners Announces New General Surgery Hospitalist Program with CarolinaEast Health System in New Bern, North Carolina
11. United Nations Secretary-General Ban Ki-moon, President Bill Clinton, Launch MASSIVEGOOD, a Citizen Solution for Funding Global Health
Post Your Comments:
(Date:10/13/2015)... Beach, FL (PRWEB) , ... October 13, 2015 , ... ... Global Laser Vision of San Diego, California. With brands including The LASIK Vision Institute ... successful procedures, making it the nationwide leader in laser vision correction. , Global Laser ...
(Date:10/13/2015)... ... ... Sir Grout of Greater Boston donated an expansive, seven room tile and ... (RMHC®). This donation was made in an effort to give back to the local ... “We believe strongly in the Ronald McDonald House Charities, and they are truly a ...
(Date:10/13/2015)... ... 13, 2015 , ... CURE Media Group, the nation’s leading ... partnership with the International Waldenstrom’s Macroglobulinemia Foundation (IWMF) to expand education ... and physicians. , “Waldenstrom’s Macroglobulinemia is a so-called ‘orphan disease’ that typically ...
(Date:10/13/2015)... ... October 13, 2015 , ... "My friend's son suffers from eczema, and ... cheeks," said an inventor from Platteville, Colo. "I came up with this kit as ... the UNTOUCHABLE to prevent a child from rubbing or scratching his or her face. ...
(Date:10/13/2015)... ... October 13, 2015 , ... Califia Farms , one ... the release of its limited edition holiday seasonal flavors: Almondmilk Holiday Nog, new ... the unique flavor combinations and delicious taste Califia Farms’ beverages are known for, ...
Breaking Medicine News(10 mins):
(Date:10/13/2015)... , Oct. 13, 2015  Synapse Biomedical Inc. ... Post Approval Study (PAS) studying the use of the ... is continuing to enroll patients. the ... to the FDA market-approved criteria. The PAS study group ... August 2014. The study has since expanded the enrollment ...
(Date:10/13/2015)... , Oct. 13, 2015  Nanomedical Diagnostics, ... use in research and diagnostics, announces the completion ... million led by Serra Ventures. ... is providing low-cost, easy-to-use monitoring and diagnostic platforms ... decisions. The funding round will enable the company ...
(Date:10/13/2015)... -- SeraCare Life Sciences, a leading partner to global in ... medicine business unit has launched its second product in ... (NGS)-based tumor profiling assays.  The Seraseq TM Solid ... mutations in key oncogenes and tumor suppressor genes as ... is offered at five additional allele frequencies. ...
Breaking Medicine Technology: